UK: Ground-Breaking Declaratory Relief From English High Court Clears The Route To Market For Humira Biosimilar

In a landmark judgment, the High Court has granted a novel type of declaratory relief to clear the route to market for a product facing a raft of pending patent applications incapable of challenge in the UK court: If the declaration serves a useful purpose, and upon considering the justice to the parties and any special reasons, the court can grant declarations that effectively offer an invisibility cloak against infringement actions based on patent applications which are later granted.

The High Court's 3 March 2017 decision in Fujifilm Kyowa Kirin Biologics v AbbVie Biotechnology [2017] EWHC 395 (Pat) marks the first declaration of its kind to be granted in the UK, and a turning point in patent litigation - allowing companies at risk of patent infringement to potentially "clear the way" even before patents are granted.

The judgment also resolves the uncertainty that remained after Arrow's battle with Merck in 2007, when the court refused to strike-out Arrow's claim for declaratory relief, but no final ruling emerged.

The highest turnover drug in the world

The case concerned AbbVie's network of patents and patent applications protecting dosing regimens for the use of its blockbuster anti-TNFα monoclonal antibody drug, Humira. Humira is used to inhibit the inflammatory effects of cell signalling protein "TNFα" in inflammatory diseases, including rheumatoid arthritis ("RA"), psoriatic arthritis ("PsA") and psoriasis. 

With a global turnover of over $16 billion and daily UK sales of around £1.2 million, Humira is the world's highest selling drug.

Confronted with the imminent expiry of its basic product patent in October 2018 (EP 0,929,578 and SPC GB/04/002), AbbVie applied for "secondary" patents claiming the use of Humira in certain dosing regimens to treat various inflammatory diseases.  

Clearing the way

In preparation for the launch of its monoclonal antibody biosimilar to Humira, in October 2015 FKB commenced litigation ("FKB1" proceedings) to clear the way of certain of AbbVie's secondary patents, seeking revocation of two of AbbVie's dosing regimen patents relating to RA and Psoriasis/PsA.  As the Patents Act 1977 provides no mechanism to challenge the validity of pending patent applications in the UK courts, FKB also sought a new type of remedy - a declaration that using its own product in the relevant dosing regimens would have been obvious or lacking in novelty at the relevant date.

Such a declaration would give FKB an invisibility cloak from future patents for those dosing regimens - if using FKB's biosimilar in those dosing regimens was obvious or lacking in novelty, it could not infringe any future patent granted in respect of those regimens.

AbbVie applied to the High Court to strike out FKB's claim, but its application was refused in March 2016, [2016] EWHC 425 (Pat). On 12 January, the court of Appeal [2017] EWCA Civ 1 agreed with the High Court - the court had jurisdiction to grant declaratory relief, at its discretion.

In an unexpected twist, two months before the trial, AbbVie abandoned or de-designated the UK from its relevant dosing regimen patent and offered the court undertakings not to obtain future patent protection in the UK for those dosing regimens. With no relevant patents subsisting, AbbVie again attempted to strike-out FKB's claim. However, Henry Carr J. [2016] EWHC 3383 (Ch) found FKB had a real prospect of success in showing that the declaration would serve a useful purpose, and the case proceeded to trial.

Samsung Bioepis and Biogen Idec commenced proceedings (Claim HP-2016-000016, the "SB" proceedings) in 2016 seeking an equivalent declaration. The trials of the FKB and SB cases were heard together in January 2017 - the parties cooperating to present a single case with joint experts. 

Declaratory relief: The law

The judge applied the following principles:

While declarations are a matter of discretion for the court, and negative declarations are unusual, where a negative declaration would help to ensure that the aims of justice are achieved, "the courts should not be reluctant to grant such declarations" (Messier-Doughty v Sabena [2001] 1 All E.R. 275, Lord Woolf [41]).

The judge considered whether, in all the circumstances, it was appropriate to make a declaration, taking into account "justice to the claimant, justice to the defendant, whether the declaration would serve a useful purpose and whether there are any other special reasons why or why not the court should grant the declaration" (Financial Services Authority v Rourke [2002] CP Rep. 14, Neuberger J).

Declaratory relief is not appropriate in all cases. "A claimant cannot seek an  Arrow declaration simply because it would like to know whether a patent application in the course of prosecution will result in a valid patent... Where, for example, it appears that the statutory remedy is being frustrated by shielding subject matter from scrutiny in the national court, it should be open to the court to intervene" [93], but "an important factor to be borne in mind... is the existence of the statutory proceedings for revocation, which should be regarded as the normal vehicle for obtaining any desired findings of invalidity" [99] (FKB1, [2017] EWCA Civ 1, Floyd LJ).

Declaratory relief: The submissions

"Useful purpose"

The main debate related to whether there was a useful purpose in granting the declaration. AbbVie argued that, by the time of the trial, there remained no useful purpose as the way had been "cleared" in the UK. By then, AbbVie had abandoned/ de-designated the relevant patents and had given undertakings.

FKB contended that a useful purpose must remain, or AbbVie would have submitted to judgment. In refusing to do so, there remained commercial uncertainty created by AbbVie's behaviour:

  1. From the outset of the litigation, AbbVie had created a moving target by delaying applications from being granted, abandoning applications (even once approved for grant) and filing duplicative "divisional" applications.
  2. AbbVie's CEO repeatedly expressed AbbVie's intention to seek injunctive relief to prevent "at-risk" launches of Humira biosimilars and FKB considered these threats to apply to Europe.

AbbVie produced no evidence at trial as to whether there was a useful purpose and, during the second week of the trial, chose not to cross-examine FKB's and SB's witnesses.

Finding on "useful purpose"

The judge indicated that he must concern himself with whether the declaration sought would serve a useful purpose in the UK. While he considered there to be a useful purpose regardless of AbbVie's intentions, he found that:

"subsequent events have confirmed, in my judgment, that AbbVie has abandoned all relevant UK patent protection in order to avoid scrutiny by the UK Court, and to prolong commercial uncertainty as to the validity of those patents" [349].

AbbVie's "intention and the objective effect is to shield its patent portfolio from examination of validity whilst continuing to file further divisionals and to threaten infringement proceedings against biosimilars, wherever they may be launched" [388].

The declaration was found to serve a useful purpose in light of ([394-410]):

  1. AbbVie's strategy of filing of divisional patent applications, perpetuating commercial uncertainty;
  2. AbbVie's public statements of confidence in its patent portfolio while shielding its patents from scrutiny by the court;
  3. commercial uncertainty arising from AbbVie's threats to enforce its patents anywhere in the world;
  4. the "chilling effect" those statements would have (including on third party suppliers) and the need to protect FKB's supply chain for the UK by addressing that "chilling effect" and providing a persuasive UK judgment reducing the risk of injunctive relief in other jurisdictions which could disrupted the UK supply chain; and
  5. the potential to promote settlement (which would have a direct benefit in the UK were AbbVie to seek to enforce other patents relating to Humira).

In considering FKB's submissions that the declaration would serve a useful "spin-off" purpose as a persuasive authority in other jurisdictions, the court accepted that while spin-off "can be very valuable", "it is important not to extend this principle too far"; "a declaration which is sought solely for the benefit of foreign courts will rarely be justified". It also rejected AbbVie's suggestion that FKB's solicitors were not qualified to make assessments of the value of a UK judgment in the EU.

In the present case, "AbbVie has abandoned its UK patent protection shortly before trial, and has a long record of similar conduct.  This is quite different from a case which has never had any connection with the United Kingdom, and is brought purely to influence foreign courts" [392]. It was found that there was more than spin-off value here. Central to this finding were the risks to the UK supply chain of injunctive relief in other jurisdictions and, given the pan-European nature of the pharmaceutical industry, in the absence of a declaration, the "chilling effect" on the market would make it more difficult for manufacturers to find European marketing partners.

In relation to AbbVie's undertakings and failure to submit to judgment, the judge commented:

"If, as AbbVie submits, the declarations have no useful purpose, and the steps that they have taken have the same effect in achieving commercial certainty, there is no coherent explanation as to why it refuses to submit to judgment, or alternatively to give an acknowledgement in the same form as the declarations" [386].

Although the undertakings would have prevented AbbVie from obtaining future UK patents claiming the relevant dosage regimens, they were "complicated" and "difficult to follow". The judge accepted FKB's submission that the declaration would provide clarity to third parties in the UK and "such clarity is necessary, given AbbVie's conduct to date, and is not provided by AbbVie's undertakings" [389-399].

Justice to the Claimants and the Defendants

FKB submitted that it was just to grant the declarations, that such determination should be made within a reasonable timeframe and that AbbVie's acts had prevented such a determination. The judge accepted that the declarations would serve a useful purpose and having heard the technical case, it was just to grant them and there would be no injustice to AbbVie in doing so.

Special reasons

The short summary of the "special reasons" for the grant of the declarations was as follows:

"On the most unusual facts of this case, there are special reasons which support the grant of the declarations. These include AbbVie's conduct of threatening infringement whilst abandoning proceedings at the last moment (in order to shield its patent portfolio from scrutiny); the amount of money at stake for the Claimants in terms of investment in clinical trials and potential damages if they launch at risk; and the need for commercial certainty, having regard to AbbVie's threats to sue for infringement throughout the world" [416].

Award of the declaration

The reasons for judge's award of the declaration centred on the unusual facts of the case - including AbbVie's patent filing strategy and its attempts to avoid adjudication on the validity of its patents. This serves as a warning to patentees: although an act may be within the rules laid down by the EPO, the UK courts can grant declaratory relief when the circumstances justify it, and a patentee's behaviour is likely to be a key factor.

The technical case

We also write briefly here on some points of interest from the technical case.

Shortly before the trial of the action, AbbVie accepted the obviousness/anticipation of a number of the dosing regimens at certain dates (in one case, that date was later than the relevant date in the declaration, and Henry Carr J. proceeded to find it obvious/anticipated at the earlier date based on a prior use).

This left only one regimen to be considered at trial (every other week dosing with 40mg in RA). FKB sought to establish the obviousness of using FKB's biosimilar in that regimen on the basis of two prior art papers by Dr Kempeni and three conference abstracts referenced in the papers.

AbbVie's prior art

AbbVie supplemented FKB's pleaded prior art with "Additional Prior Art" - every paper and conference abstract referencing Humira before the relevant date. FKB argued this was impermissible and had FKB sought to "mosaic" these publications it would not have been allowed (unless the mosaic was obvious).

Henry Carr J agreed with AbbVie. The Additional Art was "material which is not common general knowledge, which nonetheless, as a matter of routine, the skilled person would look for and find when approaching a particular problem".

However, the judge rejected AbbVie's attempts to draw conclusions from individual abstracts in the Additional Prior Art, when the pleaded Kempeni papers were an overview of (almost all) of the Additional Prior Art studies, and did not draw the conclusions AbbVie sought to draw.

Dosing regimen design

While AbbVie's experts pursued dosing regimens that would be maximally effective in every patient, the judge preferred the evidence of Prof Edwards (for FKB) that "the skilled clinician would be looking for a dosage regimen which would help the condition of the majority of patients" and that the dosing regimen would be designed "having regard also to cost considerations, patient convenience and, accordingly, patient compliance" [114].

The dosing regimens were ultimately found to be obvious in light of both of the Kempeni papers.

A warning to experts

Henry Carr J. gave a number of warnings regarding expert evidence. In discussing AbbVie's experts, he commented that while there is no issue with experts being used in multiple jurisdictions, it is not satisfactory for them to claim in the UK court that they are unable to comment upon an issue which they have commented on in other proceedings [208].

He also cautioned experts to reference their experience where it contradicts their written evidence. In relation to AbbVie's rheumatologist, he wrote:

"I am also concerned about the failure to mention in her reports that she had worked on a biological for the treatment of RA known as anakinra, the history of which contradicts material parts of her evidence. I am prepared to accept that this was a mistake, rather than a deliberate omission, but it should not have happened" [118];

"...she should have referred to anakinra and explained why she was able, nonetheless to give this evidence" [201].

To ensure experts comply with their duty to the court, the judge commented:

"it is not merely a question of an expert stating that he/she has read and understood the relevant duties. Rather, the expert needs to adhere to them strictly. This is likely to involve careful additions and alterations by the expert to draft reports, which are often worked on by many hands. Furthermore, if, during cross-examination, it becomes clear that some part of the expert report is mistaken, it is necessary to say so, rather than doggedly to adhere to the party line."

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
16 Jan 2018, Seminar, Birmingham, UK

Join Gowling WLG's pensions team as they explain some of the biggest challenges facing trustees and employers in the coming year and provide practical ways of dealing with them.

23 Jan 2018, Seminar, London, UK

Join Gowling WLG's pensions team as they explain some of the biggest challenges facing trustees and employers in the coming year and provide practical ways of dealing with them.

25 Jan 2018, Seminar, Birmingham, UK

2018 is set to be another big year in employment, with employers set to face new challenges and responsibilities. At our event, looking ahead to next year, we will be discussing four key issues you might face in 2018, providing useful tips and answering your questions.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions